Navigation Links
Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the National Academy of Sciences (1) supports the findings of several other studies that EpCAM (CD326), which is used as the target for Micromet's product candidates adecatumumab (MT201) and MT110, may be suitable as a target for eradication of so called "cancer stem cells" (CSCs). The other studies showed that CSCs from colon (2), breast (3), pancreatic (4) and prostate (5) cancers all express high levels of EpCAM, which, according to these studies, makes these cells particularly capable of causing tumors.

CSCs constitute a small percentage of tumor cells that have the potential to self-renew and to permanently repopulate a tumor with new cancer cells. CSCs appear to be resistant to various chemotherapies, which may be one of the key reasons why most current therapies cannot cure cancer through elimination of all tumor cells (6). Micromet scientists believe that the findings of EpCAM expression by CSCs in many cancers and of EpCAM being a frequently and highly expressed tumor-associated antigen (7, 8), supports Micromet's use of EpCAM for targeted therapeutics.

EpCAM is the target for Micromet's clinical-stage product candidate adecatumumab (MT201), a fully human monoclonal antibody being co-developed with Merck Serono. In addition, Micromet's BiTE(R) product candidate MT110, an anti-EpCAM/CD3-bispecific antibody construct, is currently in late preclinical development. Both product candidates are designed to recognize EpCAM- expressing cancer cells and to instruct cytotoxic cells of the immune system to eliminate such cancer cells.

"The 'seek and destroy' mechanism of our EpCAM-directed therapeutic drug can
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... 18, 2014 Since last month,s FBI shutdown ... known as the leading online black market for illegal ... in its offering of drugs and other illegal items.  ... takedowns did succeed in lowering the numbers of drugs ... the markets in August. But some new sites that ...
(Date:12/19/2014)... France , Dec. 19, 2014  Eli Lilly ... (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide ... as BioChaperone Lispro, for treatment in people with type ... Adocia,s proprietary BioChaperone® technology and is currently in Phase ... BioChaperone Lispro with the goal of optimizing glucose levels ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
(Date:12/19/2014)... 2014 This is a professional and ... Gliquidone industry with a focus on the Chinese market. ... of the Gliquidone manufacturers and is a valuable source ... in the industry. , Firstly, the report provides a ... and manufacturing technology. Then, the report explores the international ...
(Date:12/19/2014)... -- The tragic death from "rat-bite fever" of a 10-year-old ... rodents, according to a report from the U.S. Centers for ... but potentially fatal illness that should be considered in persons ... of rodent exposure is reported," said a team led by ... The case outlined in the report occurred in August of ...
(Date:12/19/2014)... Steven Reinberg HealthDay Reporter ... can,t balance on one leg for at least 20 seconds ... suggest. Difficulty standing on one leg may indicate that ... the risk for more serious strokes is high, the investigators ... "Individuals showing instability while standing on one leg, as ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of the world’s ... heart coherence and the physiology of emotions, is ... to chipset manufacturers and consumer electronics companies. The ... its HRV solutions, tap into its HRV sensor ... HRV databases and algorithms for developing consumer products. ...
(Date:12/17/2014)... NY (PRWEB) December 17, 2014 Project ... who recently brought videos of MIT economist and Obamacare ... best-selling author James O’Keefe conducted the interview, which is ... stated that there was intentional mislabeling in the Affordable ... in the bill: A two-hundred-and-fifty billion dollar per year ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... PHILADELPHIA, July 17 , , WHO: ... members of a crisis management team assisting clients ... in Jakarta,s Mega Kuningan business district., WHY: International SOS ... of medical, security, aviation, logistical and communications, ...
... children and young adults still primary targets, , FRIDAY, July ... development of a vaccine for the H1N1 swine flu is ... fall. , Initial tests of a vaccine are expected to ... and effectiveness won,t be known for about month after that, ...
... , , WASHINGTON, July 17 ... Fla., has agreed to pay the United States $1.7 million to ... Justice announced today. , , In ... Middle District of Florida, United States ex rel. Michael Flanery ...
... , WASHINGTON, July 17 The Food and Drug ... Series -- Price Reporting Basics under Medicaid, Medicare and the ... , Written by Alice Valder Curran, ... two associates at the firm, Emily S. Gebba and Sarah H. ...
... to patients, poor emotional status, study suggests , FRIDAY, ... a positive religious attitude is not linked to measures ... can lead to worse emotional and mental health, a ... with early-stage breast cancer and 86 women with late-stage ...
... , , , , ... and how best to prepare for ... ROSEMONT, Ill., July 17 Pope Benedict XVI,s fractured wrist . ... Boys of Summer. If you need an expert to discuss any of these timely ...
Cached Medicine News:Health News:Available for Interviews: Doctor, Security Specialist Assisting Victims of Jakarta Bombings 2Health News:Available for Interviews: Doctor, Security Specialist Assisting Victims of Jakarta Bombings 3Health News:Available for Interviews: Doctor, Security Specialist Assisting Victims of Jakarta Bombings 4Health News:Swine Flu Vaccine on Track for Fall: CDC 2Health News:Swine Flu Vaccine on Track for Fall: CDC 3Health News:Swine Flu Vaccine on Track for Fall: CDC 4Health News:Swine Flu Vaccine on Track for Fall: CDC 5Health News:Swine Flu Vaccine on Track for Fall: CDC 6Health News:Swine Flu Vaccine on Track for Fall: CDC 7Health News:Swine Flu Vaccine on Track for Fall: CDC 8Health News:Swine Flu Vaccine on Track for Fall: CDC 9Health News:Swine Flu Vaccine on Track for Fall: CDC 10Health News:Swine Flu Vaccine on Track for Fall: CDC 11Health News:Swine Flu Vaccine on Track for Fall: CDC 12Health News:Tampa Bay Doctor Agrees to Pay United States $1.7 Million to Resolve Medicare Fraud Allegations 2Health News:New FDLI Monograph on Federal Price Reporting Requirements Provides Essential Guidance on Commercial Strategy, Compliance Issues 2Health News:Spiritual Outlook Can Affect Mental Health in Breast Cancer 2Health News:Writing About Injuries or Surgeries? 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: